Gilead Launches HepConnect Initiative to Reduce Hepatitis C Infections in Greater Appalachia
Gilead Sciences announced HepConnect, a five-year, multi-million dollar initiative aimed at addressing the sharp increase in chronic hepatitis C (HCV) infections fueled by the nation’s…
Read More...
Read More...
